Mitchell Shawnte 4

What Happened

Mitchell Shawnte, Chief Legal Officer of Olema Pharmaceuticals (OLMA), was granted two derivative awards on February 2, 2026 totaling 276,250 option-type shares (220,000 and 56,250). The Form 4 reports an acquisition price of $0.00 and a total reported value of $0 for these awards (i.e., no cash paid at grant). This is an equity award grant (not a sale or open-market purchase).

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
• Grants: 220,000 and 56,250 derivative shares; total = 276,250.
• Price/value reported on Form 4: $0.00 / $0 (derivative awards).
• Shares owned after transaction: Not specified in the filing.
• Vesting/time & performance conditions:
  • Footnote 1: 25% of the shares subject to the option vest on Feb 2, 2027, then 1/48 of total shares vest each month thereafter, contingent on continuous service.
  • Footnote 2: Performance-based options vest only if stock-price thresholds are met during two performance periods (Feb 2, 2026 – Dec 31, 2029 and Feb 2, 2026 – Dec 31, 2030) based on a consecutive 30-day average closing price and upon Compensation Committee certification and continued service.
• Filing timeliness: Filed two days after the transaction date; no late-filing flag noted.

Context

These entries are derivative option awards rather than open-market purchases or sales; they represent potential future equity subject to time-based and performance-based vesting conditions. No immediate cash changed hands according to the filing, and vesting depends on continued service and, for part of the grant, meeting specified stock-price performance thresholds. Such grants are common for executive compensation and do not by themselves indicate an insider buying or selling shares on the open market.